814,062 Shares in Twist Bioscience Corporation $TWST Purchased by Nuveen LLC

Key Points

• Nuveen LLC has acquired 814,062 shares of Twist Bioscience Corporation, valued at approximately $31.96 million, representing about 1.36% of the company at the end of the last reporting period.
• Twist Bioscience reported earnings of ($0.47) EPS for the last quarter, which surpassed the consensus estimate, and generated revenues of $96.06 million, exceeding analyst expectations.
• The stock's performance has led to a range of analyst price target adjustments, with the average target set at $49.40, indicating a generally positive outlook despite recent price reductions from several brokerages.

Nuveen LLC purchased a new stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 814,062 shares of the company's stock, valued at approximately $31,960,000. Nuveen LLC owned approximately 1.36% of Twist Bioscience at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. ARK Investment Management LLC boosted its stake in shares of Twist Bioscience by 11.5% in the 1st quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after purchasing an additional 645,730 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 5,867,459 shares of the company's stock valued at $230,356,000 after purchasing an additional 60,276 shares in the last quarter. First Light Asset Management LLC acquired a new stake in shares of Twist Bioscience in the 4th quarter valued at approximately $56,984,000. Northern Trust Corp boosted its stake in shares of Twist Bioscience by 9.0% in the 4th quarter. Northern Trust Corp now owns 627,649 shares of the company's stock valued at $29,167,000 after purchasing an additional 51,926 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Twist Bioscience by 2.4% in the 1st quarter. New York State Common Retirement Fund now owns 452,750 shares of the company's stock valued at $17,775,000 after purchasing an additional 10,761 shares in the last quarter.

Twist Bioscience Trading Up 1.3%

Shares of NASDAQ TWST traded up $0.3440 during midday trading on Thursday, reaching $26.7940. The stock had a trading volume of 483,646 shares, compared to its average volume of 1,193,127. The company's 50 day moving average price is $33.78 and its 200 day moving average price is $36.75. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -18.48 and a beta of 2.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a twelve month low of $24.28 and a twelve month high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.07. The company had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Evercore ISI set a $46.00 price target on shares of Twist Bioscience in a research note on Monday, August 4th. The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Guggenheim reiterated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research report on Tuesday, May 6th. JPMorgan Chase & Co. cut their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Robert W. Baird cut their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $49.40.

Insiders Place Their Bets

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer directly owned 103,569 shares of the company's stock, valued at $3,951,157.35. The trade was a 2.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,678 shares of Twist Bioscience stock in a transaction on Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the transaction, the chief executive officer directly owned 645,782 shares in the company, valued at $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,089 shares of company stock valued at $217,117 in the last 90 days. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.